A Clinical Trial to Demonstrate the Efficacy of Cangrelor (PCI)

This study has been terminated.
(Insufficient evidence of the clinical effectiveness of cangrelor)
Sponsor:
Information provided by (Responsible Party):
The Medicines Company
ClinicalTrials.gov Identifier:
NCT00305162
First received: March 17, 2006
Last updated: January 13, 2012
Last verified: January 2012
  Purpose

The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.

Two (2) separate sub-studies will be conducted at selected study sites:

  • TMC-CAN-05-02-S1 "The effect of cangrelor on the pharmacodynamics of clopidogrel" to determine whether the administration of a cangrelor infusion prior to administration of a 600 mg loading dose of clopidogrel has any effect on the extent of platelet inhibition by clopidogrel
  • TMC-CAN-05-02-S2 "A cangrelor population pharmacokinetics modeling study" to develop a population pharmacokinetic (PK) model for cangrelor from data obtained from ongoing Phase III studies of patients with coronary atherosclerosis requiring percutaneous coronary intervention (PCI)

Condition Intervention Phase
Unstable Angina
Myocardial Infarction
Acute Coronary Syndromes
Drug: cangrelor (P2Y12 inhibitor)
Drug: clopidogrel (P2Y12 inhibitor)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention.

Resource links provided by NLM:


Further study details as provided by The Medicines Company:

Primary Outcome Measures:
  • All-cause mortality, MI, and IDR [ Time Frame: 48 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Death, IDR [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Enrollment: 8882
Study Start Date: April 2006
Study Completion Date: June 2010
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
placebo capsules (to match) + cangrelor bolus -(30 ug/kg) & infusion (4ug/kg/min)
Drug: cangrelor (P2Y12 inhibitor)
Bolus (30 ug/kg) & infusion (4 ug/kg/min) administered within 30 minutes of the start of PCI - infusion to continue minimum of 2 hours and no longer than 4 hours.
Active Comparator: 2
clopidrogrel capsules (600 mg) + placebo bolus & infusion (to match)
Drug: clopidogrel (P2Y12 inhibitor)
600 mg active clopidogrel given 30 minutes prior to the start of PCI.
Other Name: Plavix

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

To be included in this study, subjects must meet the following criteria:

  • Angiography demonstrating atherosclerosis amenable to treatment by PCI with or without stent implantation and diagnosis of Acute Coronary Syndrome by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age > 65 or diabetes or ST-elevation MI.

EXCLUSION CRITERIA

Subjects will be excluded from the study if they present with any of the following:

  1. Not a candidate for PCI
  2. Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (<1 month) trauma or major surgery (including by-pass surgery); currently receiving warfarin, active bleeding
  3. Impaired hemostasis: known International Normalized Ratio (INR) >1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count <100,000/µL), or history of thrombocytopenia or neutropenia associated with clopidogrel
  4. Severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization
  5. Receipt of fibrinolytic therapy in the 12 hours preceding randomization
  6. Receipt of clopidogrel dose exceeding maintenance dose (ie, >75 mg) at any time in the 5 days preceding randomization
  7. Inability to swallow study capsules
  8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours (applicable to UA and NSTEMI patients)

Subjects excluded for any of the above reasons may be re-screened for participation at any time if the exclusion characteristic has changed.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00305162

Locations
United States, Pennsylvania
Pennsylvania Hospital
Philadelphia, Pennsylvania, United States, 19107-6192
Sponsors and Collaborators
The Medicines Company
Investigators
Principal Investigator: Deepak L. Bhatt, MD The Cleveland Clinic
Principal Investigator: Robert A. Harrington, MD Duke University Medical Center and Duke Clinical Research Institute
Study Director: Simona Skerjanec, PharmD The Medicines Company
  More Information

No publications provided by The Medicines Company

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: The Medicines Company
ClinicalTrials.gov Identifier: NCT00305162     History of Changes
Other Study ID Numbers: TMC-CAN-05-02
Study First Received: March 17, 2006
Last Updated: January 13, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by The Medicines Company:
Acute Coronary Syndrome
PCI
NStemi

Additional relevant MeSH terms:
Angina, Unstable
Infarction
Myocardial Infarction
Acute Coronary Syndrome
Angina Pectoris
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Pain
Signs and Symptoms
Ischemia
Pathologic Processes
Necrosis
Clopidogrel
Cangrelor
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 16, 2014